Company intelligence / Profile preview

Beijing Feitian Zhaoye Technology Co., Ltd.

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Feitian Zhaoye Technology Co., Ltd. develops and commercializes brachytherapy treatment planning systems (TPS) specifically for radioactive particle implantation, a form of targeted radiotherapy in cancer treatment. Their FTTPS is widely used for various malignant tumors, including prostate, lung, pancreatic, liver, esophageal, and breast cancers. As of 2023, the company holds a 61.2% market share in China for brachytherapy TPS installations[1].

Therapeutic areas: Oncology
Modalities: DeviceSoftware
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Beijing Feitian Zhaoye Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Feitian Zhaoye Technology Co., Ltd..

Explore the full profile